Related Experiment Videos

Anti-inflammatory agents and antioxidants as a possible "third great wave" in cardiovascular secondary prevention

Deepak L Bhatt1

  • 1Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. bhattd@ccf.org

Insights

Despite statins and aspirin, cardiovascular disease persists. New therapies targeting inflammation and oxidative stress, like xanthophyll carotenoids, are crucial for improving outcomes in atherothrombotic disease.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biochemistry

Background:

  • Atherothrombotic disease is driven by plaque burden, hyperreactive platelets, and vascular inflammation.
  • Statins and antiplatelet agents have reduced cardiovascular events but do not eliminate disease progression.
  • A significant unmet need exists for novel therapies to improve outcomes in atherothrombotic disease.

Purpose of the Study:

  • To analyze the role of inflammation and oxidative stress as therapeutic targets in atherothrombotic disease.
  • To critically examine the history of anti-inflammatory and antioxidant therapies in cardiovascular disease.
  • To explore contemporary drug discovery processes using xanthophyll carotenoids as an example.

Main Methods:

  • Review of existing literature on atherothrombotic disease and its management.
  • Analysis of the role of inflammation and oxidative stress in cardiovascular disease.
  • Examination of the drug discovery and development pipeline for novel therapeutic agents.

Main Results:

  • Inflammation and oxidative stress are increasingly recognized as critical factors in atherothrombosis.
  • Past anti-inflammatory and antioxidant therapies have had limited success, necessitating new approaches.
  • Xanthophyll carotenoids represent a promising class of antioxidants under investigation for cardiovascular benefits.

Conclusions:

  • Targeting inflammation and oxidative stress holds potential for improving outcomes in atherothrombotic disease.
  • Novel drug discovery approaches are essential to identify and develop effective therapies.
  • Further research into agents like xanthophyll carotenoids is warranted to address the limitations of current treatments.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...